SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline

Robbins LLP issued a shareholder-solicitation notice reminding SPRY investors of the October 5, 2026 lead-plaintiff deadline in a securities class action covering purchases of ARS Pharmaceuticals shares between March 9, 2026 and June 24, 2026. The suit alleges ARS made misleadingly positive statements about the timing of expanded CVS Caremark insurance coverage for neffy; per the complaint, the stock fell over 23.9% in a single day, from $10.54 to $8.02, after ARS disclosed the coverage decision was pushed to January 2027.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.